About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- Postmenopausal women with severe osteoporosis (1,360 women, 680 per group, in secondary VERO analyses)
- Sample size
- 1360
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Comparator was risedronate only. The difference in non-vertebral fragility fractures was not statistically significant. Verified via Europe PMC on 14 November 2026.
Cited in
Teriparatide versus risedronate (VERO)
Teriparatide · Research finding
Strong
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.